The Effect of Weight Loss on Psoriasis Area Severity Index in Adult Psoriasis Patients
NCT ID: NCT01137448
Last Updated: 2013-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2010-06-30
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Weight Loss
Subjects will be enrolled in a weight loss program and will receive weight loss and nutritional counseling.
Weight Loss
Subjects will enroll in a weight loss program and participate in weight loss counseling 6 times over the course of 6 months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Weight Loss
Subjects will enroll in a weight loss program and participate in weight loss counseling 6 times over the course of 6 months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A Body Mass Index (BMI) \>/= 30
* Subject has plaque psoriasis
* A Psoriasis Area Severity Index (PASI) score \>/= 10 or a total body surface area (BSA) affected by psoriasis \>/= 10%
* Capable of reading, understanding, and signing a consent form
* Females of childbearing potential must have negative urine pregnancy test on Day 0, and agree to a medically effective method of birth control (as determined by the investigator)
Exclusion Criteria
* If they are on systemic therapy for their psoriasis
* Female subjects who are pregnant or planning to become pregnant
* Patients with a history of anorexia nervosa, bulimia, or other diseases that would make a weight loss program a risk to their health
* Subjects unable to comply with study protocol
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
The University of Texas Health Science Center, Houston
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adelaide Hebert
Professor, Director - Pediatric Dermatology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adelaide Hebert, MD
Role: PRINCIPAL_INVESTIGATOR
University of Texas Medical School - Houston
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Texas Dermatology Clinical Research
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.